Last reviewed · How we verify
NCT07421479: PDO-Mercurial
Patient-Derived Breast Cancer Organoids for Therapeutic Extracellular Vesicle Isolation (PDO-Mercurial01)
trial testing Blood and tumor tissue collection in Invasive Breast Cancer in 50 participants. Participants enrolled and being followed up; not accepting new ones.
28 October 2027
Quick facts
| Lead sponsor | Istituti Clinici Scientifici Maugeri SpA |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 January 2025 |
| Primary completion | 28 October 2027 |
| Estimated completion | 28 October 2027 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Blood and tumor tissue collection
Conditions studied
- Invasive Breast Cancer — all drugs for Invasive Breast Cancer →
Sponsor
Istituti Clinici Scientifici Maugeri SpA
Who can join
18 and older, female only, with Invasive Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to establish organoid cultures, which are three-dimensional in vitro tumor models capable of supporting the long-term ex vivo growth of tumor cells derived from patients with breast carcinoma. These organoids will be used for the isolation of extracellular vesicles (EVs), which are naturally released by cells and have the ability to selectively recognize tumor tissue. Due to these properties, EVs represent promising vectors for the targeted delivery of diagnostic agents, with potential applications in fluorescence-guided surgery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07421479
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Invasive Breast Cancer
Currently open trials in the same condition.
- NCT06677944 — Preoperative Partial Breast Irradiation in Early-Stage Breast Cancer · Phase 2 · recruiting
- NCT05795101 — TRUDI: TDXD+Durva in HER2+/Low IBC · Phase 2 · recruiting
- NCT05383196 — Onvansertib + Paclitaxel In TNBC · Phase 1, PHASE2 · active not recruiting
- NCT05412225 — A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction · Phase 1 · recruiting
- NCT04368702 — CONFIRM: Magnetic Resonance Guided Radiation Therapy · NA · recruiting
Other Istituti Clinici Scientifici Maugeri SpA trials
Trials by the same sponsor.
- NCT07521436 — Awareness of Risk Factors and Perception of Cardiovascular Risk in Secondary Prevention Among Women and Men · not yet recruiting
- NCT07451977 — Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia · NA · recruiting
- NCT07448181 — Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdema · recruiting
- NCT07432204 — Therapeutic Music Listening in Post Stroke Patients. · NA · recruiting
- NCT07399418 — TRIAD - Tracking Risk in Integrated Alzheimer's Diagnostics. · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07421479 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istituti Clinici Scientifici Maugeri SpA
- Last refreshed: 19 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07421479.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing